Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease by Rosa, Alexandra Isabel et al.
Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse
Model of Parkinson’s Disease
Alexandra Isabel Rosa1 & Sara Duarte-Silva2,3 & Anabela Silva-Fernandes2,3 & Maria João Nunes1 &
Andreia Neves Carvalho1 & Elsa Rodrigues1,4 & Maria João Gama1,4 & Cecília Maria Pereira Rodrigues1,4 &
Patrícia Maciel2,3 & Margarida Castro-Caldas1,5
Received: 24 January 2018 /Accepted: 3 April 2018
# Springer Science+Business Media, LLC, part of Springer Nature 2018
Abstract
Parkinson’s disease (PD) is characterized by severe motor symptoms, and currently there is no treatment that retards disease
progression or reverses damage prior to the time of clinical diagnosis. Tauroursodeoxycholic acid (TUDCA) is neuroprotective in
the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD; however, its effect in PD motor symptoms has
never been addressed. In the present work, an extensive behavior analysis was performed to better characterize theMPTPmodel of
PD and to evaluate the effects of TUDCA in the prevention/improvement of mice phenotype.MPTP induced significant alterations
in general motor performance paradigms, including increased latency in the motor swimming, adhesive removal and pole tests, as
well as altered gait, foot dragging, and tremors. TUDCA administration, either before or after MPTP, significantly reduced the
swimming latency, improved gait quality, and decreased foot dragging. Importantly, TUDCAwas also effective in the prevention
of typical parkinsonian symptoms such as spontaneous activity, ability to initiate movement and tremors. Accordingly, TUDCA
prevented MPTP-induced decrease of dopaminergic fibers and ATP levels, mitochondrial dysfunction and neuroinflammation.
Overall, MPTP-injected mice presented motor symptoms that are aggravated throughout time, resembling human parkinsonism,
whereas PDmotor symptoms were absent or mild in TUDCA-treated animals, and no aggravation was observed in any parameter.
The thorough demonstration of improvement of PD symptoms together with the demonstration of the pathways triggered by
TUDCA supports a subsequent clinical trial in humans and future validation of the application of this bile acid in PD.
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Introduction
The cellular mechanisms underlying dopaminergic cell death
in Parkinson’s disease (PD) are still not fully understood, but
neuroinflammation, mitochondrial dysfunction and oxidative
stress are thought to contribute to dopaminergic cell loss in
both familial and sporadic cases [1, 2].
Glia play a key role in the antioxidant defense, as well as in
supplying molecules to support and monitor the neuronal micro-
environment [3]. When activated by dying neurons, these cells
are known to phagocyte cellular debris and to secrete a number
of pro-inflammatory mediators [1, 4, 5], further contributing to
neuronal degeneration, hence creating a vicious cycle of inflam-
mation and cell death, which exacerbates and propagates the
neurodegenerative process [6]. Indeed, glial activation plays an
important role in the progression of neuronal dysfunction in PD,
as reactive microglia and astrocytes, and increased levels of cy-
tokines have been reported in PD patient’s brains [7–13].
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Post-mortem observations in PD patients have also re-
vealed decreased activity of mitochondrial Complex I in the
Substantia nigra pars compacta (SNpc), platelets and skeletal
muscle [14–16]. The fact that mitochondrial inhibitors, such
as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) that
recapitulate PD pathological features [17–19], can induce glial
activation and induction of pro-inflammatory cytokines [20],
further reinforces the idea that mitochondrial dysfunction is
involved in PD pathogenesis. Epidemiological studies re-
vealed that approximately 90% of PD cases have a sporadic
origin, and the remaining 10% are familial forms of the dis-
ease [21]. One gene responsible for monogenic PD, is PARK2
that encodes for parkin, an E3 ubiquitin ligase that has been
demonstrated to be involved in different aspects of mitochon-
drial turnover [22]. Mutations in parkin are the most common
cause of early onset PD [21, 23]. Interestingly, wild-type
parkin dysfunction also plays a pivotal role in sporadic PD,
due to nitrosative and oxidative stress-induced post-transla-
tional modifications [24, 25]. Together with phosphatase and
tensin homolog (PTEN)-induced putative kinase 1 (PINK1),
parkin regulates mitophagy [22]. On the other hand, parkin
regulates mitochondrial biogenesis by modulating the levels
of parkin interacting substrate (PARIS), a transcriptional re-
pressor of peroxisome proliferator-activated receptor gamma
coactivator-1alpha (PGC-1alpha) [26]. Interestingly, parkin
also triggers the expression of DJ-1, a multi-functional anti-
oxidative protein, via transcriptional repression of p53 [27].
There is currently no treatment that significantly retards
disease progression or reverses damage prior to the time of
clinical diagnosis in PD. Symptomatic therapeutic approaches
currently used to restore dopamine levels and alleviate motor
symptoms have associated long-term usage secondary ef-
fects [28]. Hence, there is still an unmet need for disease-
modifying therapies. The fact that mitochondrial impair-
ment and oxidative stress are early events in the progres-
sion of PD makes them important therapeutic targets and
renders the pharmacological modulation of oxidative stress
and the clearance of dysfunctional mitochondria a promis-
ing therapeutic approach in PD.
Tauroursodeoxycholic acid (TUDCA) is the endogenous
taurine conjugate of ursodeoxycholic acid (UDCA), a hydro-
philic bile acid that is approved by the U.S. Food and Drug
Administration (FDA) for the treatment of certain cholestatic
liver diseases. It is orally bioavailable, crosses the blood-brain
barrier, and is relatively nontoxic. There is a growing body of
research on the potential therapeutic effects of TUDCA on a
wide variety of non-liver diseases, particularly in neurodegen-
erative disease models. In fact, TUDCA is neuroprotective in
mouse models of Huntington’s and Alzheimer’s disease
[29–32]. Importantly, our previous work demonstrated that
TUDCA is neuroprotective in the MPTP mouse model of
PD [33–35]. The actual mechanisms underlying TUDCA neu-
roprotection in experimental models of PD may be multiple,
including activation of the pro-survival Ser/Thr kinase Akt
and anti-oxidative mechanisms dependent on nuclear factor
E2-related factor 2 (Nrf2) pathway, as well as parkin-
mediated mitochondrial turnover [33–35].
Surprisingly, reports on the effects of MPTP treatment on
motor dysfunction are scarce. Animal performance in conven-
tional motor tests, such as the rotarod test, are conflicting and
different toxin administration protocols as well as different test
variants make comparisons between studies difficult [36–38].
In addition, to the best of our knowledge, the impact of
TUDCA treatment on the motor performance of MPTP-
insulted mice has never been demonstrated.
Herein, an extensive behavior analysis was performed to
evaluate the effects of TUDCA in the prevention/
improvement of the phenotype of MPTP-treated mice, and
to better characterize this model of PD. The cellular mecha-
nisms underlying these effects were also evaluated. Our work
shows that a single administration ofMPTP induces long-term
severe motor coordination deficits in C57BL/6 mice.
Importantly, administration of TUDCA, either before or after
MPTP, was effective in rescuing the MPTP-induced motor
impairments. Although TUDCA dosage used in this in vivo
experimental work may be further optimized to consistently
maintain the protective effects throughout the entire experi-
mental time course, the results suggest that TUDCA is a prom-
ising candidate for subsequent clinical studies in PD.
Materials and Methods
Ethics Statement
All procedures were conducted in accordance with European
regulations (European Union Directive 2010/63/EU). Animal
facilities and the people directly involved in animal experi-
ments (A.I.R., S.D.S.) were certified by the Portuguese regu-
latory entity - Direcção Geral de Alimentação e Veterinária.
All protocols were approved by the Animal Ethics
Committee of the Life and Health Sciences Research
Institute, University of Minho.
Animals and Drug Administration
Twelve-week-old male C57BL/6 mice were purchased from
Charles River and housed in groups of 4 or 5 animals in filter-
topped polysulfone cages 267 × 207 × 140 mm (370 cm2 floor
area) (Tecniplast, Buguggiate, Italy), with corncob bedding
(Scobis Due, Mucedola SRL, Settimo Milanese, Italy) in a
conventional animal facility. All animals were maintained un-
der standard laboratory conditions: an artificial 12 h light/dark
cycle (lights on from 8:00 to 20:00 h), with an ambient tem-
perature of 21 ± 1 °C and a relative humidity of 50–60%; the
mice were given a standard diet (4RF21, Mucedola SRL,
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Settimo Milanese, Italy) and water ad libitum. Health moni-
toring was performed according to FELASA guidelines [39,
40] confirming the Specified Pathogens status of sentinel an-
imals maintained in the same animal room. Humane endpoints
for experiments were defined (20% reduction of the body
weight, inability to reach food and water, presence of wounds
in the body, dehydration), but not needed in practice, as ani-
mals did not reach these endpoints in the study period.
The acute MPTP (Sigma) paradigm (single dose, 40 mg/Kg,
i.p.) was used to recapitulate sporadic PD. This model is highly
accepted allowing an accurate time-dependent analysis of
nigro-striatal neuroadaptive changes [41–43]. TUDCA
(Sigma) dose (50 mg/Kg, i.p., for 3 days) was based on its
pharmacokinetics, and on our previous experience [34, 35, 44].
Mice were sacrificed at different time-points post-MPTP
injection (p.i.). For the long-term evaluation scheme, animals
were divided in 4 groups:
i) Control: mice that received vehicle (saline)
ii) MPTP: mice treated with a single injection of MPTP
iii) TUDCA+MPTP: mice that received daily injections of
TUDCA for 3 consecutive days. At day 3, 6 h after
TUDCA administrationmice receivedMPTP injection.
iv) MPTP+TUDCA: mice treated with MPTP followed by
daily injections of TUDCA for 3 consecutive days. The
first TUDCA injection (at day 1) was performed 3 h
after MPTP. At this time-point MPP+ levels peak in the
striatum following a 40 mg/Kg single MPTP injection
[43], and it is the time that we and others have demon-
strated to be the onset of the active phase of MPTP-
induced dopaminergic neurodegeneration [33, 43, 45].
All mice from these 4 groups were sacrificed 52 days p.i.
together with controls.
Additionally, we used a short-term animal evaluation
scheme also composed by 4 groups as follows:
i) Control: mice that received vehicle (saline)
ii) MPTP: mice treated withMPTP, and sacrificed 3 h after
MPTP administration
iii) TUDCA+MPTP: mice that received daily injections of
TUDCA for 3 consecutive days, followed by MPTP
administration at day 3, 6 h after the last TUDCA in-
jection. These animals were sacrificed 3 h after MPTP
administration
iv) MPTP+TUDCA: mice administered with MPTP
followed by daily injections of TUDCA for 3 days,
starting at day 1, 3 h after MPTP injection. These mice
were sacrificed 6 h after the last TUDCA injection.
TUDCA on its own was shown to have no impact in motor
performance in the open arena and in the rotarod paradigms in
rats and mice, when administered i.p. or s.c., respectively [29,
46]. Unpublished work from our labs has also shown that
TUDCA given orally to mice for several weeks does not affect
performance in a set of motor behavior paradigms (Duarte-
Silva, unpublished). Therefore, to minimize the number of
animals used, according to the principles of the 3R’s, an ani-
mal group treated with TUDCA only was not included in our
experiments.
After behavioral assessment, animals were deeply anesthe-
tized with a mixture of ketamine hydrochloride (150 mg/Kg)
plus medetomidine (0.3 mg/Kg) and sacrificed by exsangui-
nation perfusion with saline. Brains were collected and sepa-
rated into hemispheres: one hemisphere was destined to im-
munohistochemistry and was immediately embedded in OCT
and frozen at −80 °C for further processing in the cryostat. The
other hemisphere was dissected as previously described [45]
to remove the entire midbrain region, containing the SNpc,
and the whole striatum, for protein extraction. All behavioral
and biochemical studies were performed by investigators
blind to the treatment conditions.
Behavioral Analysis
To register the acute effects of MPTP in C57BL/6 mice, the
animals were videotaped for 5 min, 90 min after the MPTP
injection. Two independent experimenters analyzed all the
videos. Analyzed parameters included palpebral closure, sali-
vation, fur erection, tail erection, resting time, spontaneous
activity and vertical exploratory activity.
Mouse behavior assessment was performed at 7, 30 and
45 days p.i.. Body weight was registered in all time-points
analyzed. Since the rotarod protocol may cause fatigue to
the animals, this test and other phenotypic assessments were
performed in alternate weeks.
Motor Swimming Test
To analyze voluntary locomotion, mice were trained for 2
consecutive days (3 trials each animal) to cross a clear perspex
water tank to a safe platform at the end, as previously de-
scribed [47, 48].
The perspex tank was 100 cm long and the platform at the
end was made from black perspex. The latency to cross the
water tank was measured from a distance of 60 cm (the tank
was labeled with a blue line to mark the initiation). The water
temperature was monitored to 23 °C using a thermostat. Mice
were tested for 3 consecutive days (2 trials per animal) and the
latency to traverse the tank was registered by the
experimenter.
Adhesive Removal
A round adhesive (8 mm diameter) was placed on the mouse
snout and the time the animal took to remove it was registered.
Mol Neurobiol
Time values were measured in 3 consecutive days starting at
day 7, 30 and 45 p.i.
Pole Test
Mice were placed facing up on top of a pole (37.5 cm long)
located in their cages. The time the animals took to turn down
and to reach the cage was registered. If the animal fell or did
not turn down after 5 min, this was considered one failed trial.
Time values were registered in 3 consecutive days starting at
day 7, 30 and 45 p.i.
Beam Walk Balance Test
This test was performed to assess balance and fine motor
coordination, as previously described [47, 48]. The animals
were trained during 3 days in the square beam (12 mm). In the
fourth day, they were tested in the training beam and also in
one round beam (17 mm). If the animal fell or turned around
in the beam, this was considered one failed trial. Each animal
had the opportunity to fail twice in each beam. The time the
animal took to cross the beam was counted, and time was
discounted if the animal stopped in the beam.
Rotarod
Mice were tested in a rotarod apparatus specific for mice (TSE
systems, Bad Homburg, Germany) to evaluate their motor
performance. The animals were subjected to 4 trials in 4 con-
secutive days on an acceleration rod (4–40 rpm, for a maxi-
mum of 5 min) with a 20-min-long interval between each trial
and the latency to fall was registered automatically by the
software.
SHIRPA
The protocol for phenotypic assessment used in this study was
based on the primary screen of the SHIRPA protocol, which
mimics the diagnostic process of general neurological and
psychiatric examination in humans [49].
Footprint Analysis
The footprint pattern was obtained to assess gait as described
previously [47, 48]. To evaluate the severity of foot dragging,
the footprinting pattern was classified at each time-point
considering six consecutive steps (0 = absent/mild, drag-
ging evident in up to three steps; 1 = mild, dragging in
more than three steps out of six; 2 = severe, dragging in
all six steps). The stride length was measured manually
as the distance between two paw prints. Three measure-
ments were obtained in consecutive steps.
Immunohistochemistry
Immunohistochemistry was performed using standard proto-
cols. Briefly, cryostat coronal slices at the level of the
midstriatum (Bregma 1.00) and SNpc (Bregma −3.20) were
fixed in 4% PFA for 30min and rinsed in PBS twice for 5 min.
Tyrosine-Hydroxylase (TH) detection was performed using
the protocol described previously [50]. TH-positive fiber den-
sity was quantified in the striatum (n = 3 for each condition, 2–4
slides per animal). Digital slides were obtained using the high-
resolution scanner NanoZoomer S60 (Hamamatsu, Japan),
allowing whole slide imaging (objective lens 20×). After digital
slide acquisition, TH-positive fiber densitometry was deter-
mined using ImageJ software (integrated density) (National
Institutes of Health, USA) and normalized for total area.
For detection of glial fibrillary acidic protein (GFAP) and
ionized calcium binding adaptor molecule 1 (Iba-1), after fix-
ation, slices were processed as previously described [33].
Fluorescence images of 10–15 random microscopic fields
were acquired per sample, under 400x magnification, using
a fluorescence microscope (model AxioScope.A1) with inte-
grated camera AxioCam HR (Carl Zeiss, Inc). The results
were expressed as the percentage of total area, using the
ImageJ software analysis (National Institutes of Health).
Control experiments for non-specific binding were per-
formed in parallel by omission of the primary antibody.
Information regarding the antibodies used is provided in
Supplementary Table I.
Western Blot Analysis
Protein extracts were prepared from striatum and midbrain
fragments as described previously [35]. Briefly, brain frag-
ments were homogenized in PBS supplemented with
Complete Mini Protease Inhibitor Cocktail (Roche) using a
tissue grinder and centrifuged at 3000 r.p.m. for 10 min, at
4 °C. The supernatant was discarded, and the pellet suspended
in lysis buffer (20 mM Tris-HCl (pH 7.5), 150 mM NaCl,
1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium
pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4,
1 μg/ml leupeptin) supplemented with Complete Mini
Protease Inhibitor Cocktail, 200 mM Na3VO4 and 1 M NaF,
and further incubated 30 min on ice. After 6 times sonication
for 5 s, samples were centrifuged at 13000 r.p.m. for 15min, at
4 °C, and the supernatants collected and stored at −80 °C.
Protein concentration was determined using the Bradford
method according to the manufacturer instructions. Brain tis-
sue extracts were added (5:1) to denaturing buffer (0.25 mM
Tris-HCl, pH 6.8, 4% SDS, 40% glycerol, 0.2% bromophenol
blue, 1% β-mercaptoethanol), and boiled for 5 min. Brain
tissue extracts were subjected to SDS-PAGE gels and
electrotransferred to Immobilon P membranes (Millipore,
Bedford, MA, USA). Immunoblot was performed using
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specific primary antibodies indicated in Supplementary
Table I. The immunocomplexes were visualized by chemilu-
minescent detection with ECLWestern blotting detection re-
agent or SuperSignal® West Femto Maximum Sensitivity
Substrate (Thermo Fisher Scientific) in a ChemiDoc™ MP
imaging system from Bio-Rad Laboratories (Hercules, CA,
USA). β-actin or GAPDH were used as a loading control.
The relative intensities of protein bands were analyzed using
the Image Lab™ analysis software from Bio-Rad
Laboratories.
Measurement of ATP Levels
ATP levels were assessed with the ATP-Glo™Bioluminometric
Cell Viability Assay (Biotium, Hayward, CA, USA), according
to the manufacturer’s instructions. Briefly, midbrain protein ex-
tracts were assayed for luciferase activity in a luminometer
(Berthold Systems), and results were normalized to total protein
content as previously described [35]. Each condition was
assayed in triplicate.
Statistical Analysis
The experimental unit used in this study was a single animal.
Continuous variables with normal distributions (Kolmogorov-
Smirnov (K-S) test p > 0.05) were analyzed with the two-way
ANOVA repeated measures (Factors: time-point and treatment).
Behavioral data were subjected to the nonparametric Mann-
WhitneyU test or pair wise Kruskal-Wallis when variables were
non-continuous or when a continuous variable did not present a
normal distribution (K-S test p< 0.05). Categorical variables in
the SHIRPA protocol were analyzed by contingency tables
(Fisher’s exact test). All statistical analyses were performed using
SPSS 22.0 (SPSS Inc., Chicago, IL).
IHC, WB analysis and ATP measurement data are
expressed as mean ± SEM values. Data were analyzed by
one-way ANOVA and differences between groups were de-
termined by post hoc Bonferroni’s test, using GraphPad Prism
5.0 (San Diego, CA, USA).
A critical value for significance of p < 0.05 was used
throughout the study.
Results
Mouse Welfare Assessment During the Acute Phase
of MPTP Toxicity
Mice treated with saline (vehicle), MPTP or TUDCA before
MPTP injection were videotaped for 5 min, 90 min after
MPTP injection (during the acute phase of MPTP toxicity),
and were evaluated for different welfare parameters.
We observed no differences in palpebral closure or saliva-
tion between the groups (Fig. 1a, b). However, around 30% of
the MPTP-injected animals exhibited an elevated tail, i.e. a
BStraub tail^ phenomenon (p = 0.051, Fig. 1c). Fur erection
(Fig. 1d) was found in all animals treated with MPTP in the
presence or absence of TUDCA (p < 0.001). During this initial
assessment, MPTP-injected animals were markedly less ac-
tive than vehicle-treated animals spending more time immo-
bile (p < 0.001, Fig. 1e), less time moving spontaneously
(p < 0.001, Fig. 1f) and less time exploring (given by the rear-
ing natural behavior, p < 0.001, Fig. 1g). Pre-treatment with
TUDCA did not prevent these acute effects of MPTP, except
for the Straub tail. Interestingly, animals treated with TUDCA
prior to MPTP administration showed absence of this pheno-
type, and were similar to controls (Fig. 1c).
Motor Coordination and Gait Characterization
As expected, mice gradually increased their body weight with
age and there were no differences in weight variation between
groups (Supplementary Fig. 1a).
Motor coordination was assessed using themotor swimming
test. Administration of a single dose of MPTP significantly
increased swimming latency of the animals throughout the time
course of the experiment (p < 0.001, Fig. 2a). The swimming
pattern of these animals was also clearly altered: while vehicle-
treated mice presented a straight-forward pattern, the MPTP-
treated mice presented a more angled pattern (zigzag swim-
ming), touched the pool wall more frequently and used their
tails to aid the swimming task (Supplementary movies).
Notably, when animals were treated with TUDCA before or
after MPTP, the latency to cross the pool and the swimming
pattern were similar to control and significantly different from
MPTP-treated mice (p < 0.001 vs MPTP, Fig. 2a).
MPTP-injected animals showed abnormal gait quality
(qualitative assessment) 30 days p.i. (p < 0.05, Fig. 2b), an
effect that was prevented by TUDCA treatment prior to or
after MPTP (p < 0.05 vs MPTP, Fig. 2b). However, the effect
of MPTP in gait quality seems to be transient since the ob-
served gait abnormalities were not maintained 45 days p.i.
(Fig. 2b).
Foot-dragging was detected in mice treated with MPTP at
days 7, 30 and 45 after MPTP injection, (p < 0.01, 0.05 and
0.001, respectively, Fig. 2c). Interestingly, this phenotype was
prevented in animals treated with TUDCA before or after
MPTP, particularly at 45 days p.i. (p < 0.01 vs MPTP, Fig.
2c). Importantly, while animals exposed to MPTP showed
significant symptom aggravation, TUDCA treatment was able
to improve this phenotype over time.
No differences were found between animal groups in the
square (12 mm) and in the round (11 mm) beam test (balance
evaluation), nor in the rotarod test or in the stride length de-
termination (Supplementary Fig. 1b-e).
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Fig. 1 Initial mouse welfare assessment. Ninety min after MPTP
injection, mice from vehicle, MPTP and TUDCA plus MPTP groups
were videotaped for 5 min and evaluated for several parameters as
follows: a Palpebral closure, b salivation, c tail elevation, d fur erection,
e resting time, f spontaneous activity, and g vertical exploratory activity.
n = 14–17 for each group. Data are presented as mean ± SD of the
different groups. ***p < 0.001 using the Mann-Whitney test
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Evaluation of Spontaneous Activity
Spontaneous activity was characterized in terms of vertical
movements counted while animals explored a cylinder view-
ing jar (rears), in terms of horizontal movement in an arena
(number of squares crossed) and qualitatively (scored by the
experimenter as normal, hypoactive and hyperactive). Results
presented in Fig. 3a indicate that rearing behavior did not
differ between animal groups during the duration of this trial.
Accordingly, horizontal activity was also not significantly al-
tered by MPTP administration. However, 7 days p.i. horizon-
tal activity tended to be reduced in MPTP-treated mice as
compared to vehicle-treated, and animals treated with
TUDCA before MPTP exhibited an improved phenotype
compared to MPTP-treated mice (p < 0.05 vs MPTP,
Fig. 3b). Regarding qualitative assessment of spontaneous
activity (Fig. 3c), mice injected with MPTP showed a signif-
icant effect 7 days p.i., and a mild effect in the subsequent
time-points evaluated (p < 0.05). Importantly, MPTP-induced
hyperactivity was prevented by TUDCA administration either
before or after MPTP.
Evaluation of the Ability to Initiate Movement,
Tremors, Tail Position and Hindlimb Clasping
To evaluate bradykinesia in mice we determined the ability of
animals to initiate movement by using the adhesive removal
test. As expected, MPTP-injected animals were significantly
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Fig. 2 TUDCA improves the motor performance of MPTP-treated mice.
Evaluation of mice motor performance using a the motor swimming test,
b gait quality (qualitative assessment), and c the foot dragging phenotype.
n = 14–17 for each group used. Data are presented as mean ± SD of the
different groups. a ***p < 0.001 using repeated measures ANOVA con-
sidering time-point and treatment factors. b, c *, **, and *** p < 0.05,
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slower to remove the adhesive that was placed on their snouts
than vehicle-treated mice at 45 days p.i. (p < 0.001, Fig. 4a).
Relevantly, at that time-point TUDCA treatment ameliorat-
ed mice ability to remove the adhesive, when administered
before or after MPTP (p < 0.001 vs MPTP). The ability to
initiate movement was also evaluated by the pole test.
MPTP administration increased mice latency to turn down-
ward at all evaluated time-points (7 days, p < 0.05; 30 and
45 days, p < 0.001, Fig. 4b). In contrast, TUDCA adminis-
tration, prior to or after MPTP, improved this phenotype,
particularly at 30 days p.i. (p < 0.05 vs MPTP, Fig. 4b).
However, the time the animals took to reach the cage in
the pole test was similar in all groups (Supplementary
Fig. 2). Forty-five days p.i., the latency to initiate move-
ment in the arena was significantly increased in MPTP-
injected animals as compared to the vehicle-injected group.
Importantly, TUDCA treatment prior to MPTP administra-
tion was able to significantly improve this phenotype
(p < 0.05, Fig. 4c). Together, our data indicate that
MPTP-treated mice have an aberrant phenotype regarding
movement initiation that was corrected by TUDCA admin-
istration either before or after exposure to the neurotoxin.
Besides bradykinesia, tremors are also a key feature of
PD [51]. Therefore, we have evaluated this symptom in
MPTP-treated mice. MPTP-injected animals presented
tremors since 7 days p.i., that were sustained and increas-
ingly more severe throughout the course of the experi-
ments (p < 0.01, Fig. 4d). Importantly, TUDCA was able
to ameliorate this symptom at 30 days when administered
after MPTP (p < 0.01 vs MPTP, Fig. 4d), and at 45 days
when administered either before or after MPTP (p < 0.05
vs MPTP, Fig. 4d). Interestingly, mice treated with
TUDCA after MPTP administration only showed mild
tremors that ameliorated over time.
In addition, 30 days after injection with MPTP, a Straub tail
reaction was found in 50% of the MPTP-injected mice
(p < 0.01, Fig. 4e). This phenotype was significantly less fre-
quent in animals that were treated with TUDCA after MPTP
(p < 0.05 vs MPTP, Fig. 4e). Importantly, although animals
from the 3 experimental groups showed a transient symptom
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aggravation 30 days p.i., at 45 days a Straub tail reaction was
only exhibited in animals that were injected with MPTP.
Hindlimb clasping was also evaluated as a measure of basal
ganglia dysfunction [52]. MPTP-treated mice exhibit signifi-
cant hindlimb clasping from 7 days p.i. onwards, with symp-
tom aggravation from 7 to 30 days p.i, (p < 0.05, Fig. 4f). On
the other hand, although mice treated with TUDCA after
MPTP administration showed mild and severe limb clasping
7 days p.i., this symptom improved over time and was no
longer detected at 45 days post the neurotoxic insult.
Importantly, hindlimb clasping was never observed when an-
imals were pre-treated with TUDCA, at any time-points eval-
uated. In fact, TUDCA improved this phenotype 7 days p.i.
when administered before or after the neurotoxin (p < 0.05 vs
MPTP, Fig. 4f), and 30 days p.i, when administered before
MPTP (p < 0.05 vsMPTP, Fig. 4f). Other parameters included
in the SHIRPA protocol were evaluated and no differences
were found between experimental groups (listed in
Supplementary Table II).
Neuroprotective Effect of TUDCA
Against MPTP-Induced Neurodegeneration
To evaluate dopaminergic neuron degeneration, mouse
coronal brain slices at the level of the midstriatum were
subjected to immunohistochemistry against TH (Fig. 5a).
In accordance with the behavioral data, densitometry anal-
ysis of TH-positive fibers showed a significant reduction
in MPTP-treated mice striatum (p < 0.05), which was
prevented by TUDCA when administered prior to MPTP
(p < 0.05, Fig. 5a). These results also show that in animals
treated with TUDCA after MPTP, and in spite of some
beneficial effects at the behavior level, TH-positive fiber
density was not significantly different from MPTP-
injected mice.
To better characterize the degenerative effects triggered by
MPTP in this work, we determined ATP levels in mouse brain
extracts. In the striatum, despite the fact that there was a clear
tendency for ATP levels to be decreased in MPTP-treated
a
140
145
150
155
160
165
170
D
en
si
to
m
et
ry
 o
f T
H
+ 
fib
er
s
(d
en
si
ty
/ μ
m
2 )
*
*
0
50
100
150
p-
AM
PK
 e
xp
re
ss
io
n 
in
 S
T 
(%
 o
f c
on
tro
l)
*
**
p-AMPK
β-Actin
0
50
100
150
AT
P 
le
ve
ls
 in
 S
T 
(%
 o
f c
on
tro
l)
0
50
100
150 ***
*
AT
P 
le
ve
ls
 in
 M
B 
(%
 o
f c
on
tro
l)
0
50
100
150
200
*
p-
AM
PK
 e
xp
re
ss
io
n 
in
 M
B
(%
 o
f c
on
tro
l)
p-AMPK
β-Actin
b
d
c
e
Fig. 5 Neuroprotective effect of TUDCA against MPTP-induced neuro-
degeneration. a Microscopy images of TH-positive fibers in the striatum
from vehicle, MPTP, TUDCA prior to MPTP or TUDCA after MPTP-
treated mice, sacrificed 52 days p.i. Scale bar = 200 μm. TH-positive
fibers densitometry was determined with the ImageJ software and nor-
malized for total area. *p < 0.05 using the Mann-Whitney test. ATP levels
were quantified in mouse striatum (b) and midbrain (c) extracts. Levels of
p-AMPK were determined in the striatum (d) and midbrain (e) by
Western blot analysis. Representative p-AMPK immunoblots and relative
band intensity are shown. β-Actin was used as loading control. Relative
band intensity was quantified using the Image Lab™ software and
expressed as percentage of control. Data represent mean values ± SEM
of at least three independent experiments, indicated as percentage of
control. *, **, and *** p < 0.05, 0.01, and 0.001, respectively, using
one-way ANOVAwith Bonferroni’s post hoc test
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mice, no differences were found between groups (Fig. 5b).
However, in the midbrain, MPTP-treated mice showed a sig-
nificant decrease of ATP levels as compared to vehicle-treated
animals (p < 0.05, Fig. 5c). Importantly, pre-treatment with
TUDCA prevented the decrease of ATP found in MPTP-
treated animals (p < 0.05, Fig. 5c). Although mice that were
treated with TUDCA after MPTP showed ATP levels similar
to the ones found in controls (Fig. 5c), no significant differ-
ences were detected between MPTP and MPTP+TUDCA
groups.
To further evaluate the protective role of TUDCA on
ATP depletion induced by MPTP, we evaluated the phos-
phorylated levels of the energy sensor AMPK. Strikingly,
results show that in the striatum of TUDCA-treated ani-
mals the levels of activated AMPK (p-AMPK) were signif-
icantly higher than in MPTP-treated mice (TUDCA prior
to MPTP: p < 0.01; TUDCA after MPTP: p < 0.05 Fig. 5d).
Accordingly, in the midbrain extracts from animals treated
with TUDCA before MPTP the levels of p-AMPK were
also significantly higher than in MPTP-treated mice
(p < 0.05, Fig. 5e).
Altogether these results suggest that TUDCA prevents
MPTP-induced dopaminergic neurodegeneration.
Effect of TUDCA on Mitochondrial
Homeostasis-Associated Proteins in MPTP-Treated
Mice
We have previously shown that at early time-points after MPTP
injection (3 and 6 h), pre-treatment with TUDCA promotes
mitophagy via the E3 protein-ubiquitin ligase parkin [35].
Thus, to evaluate the effect of TUDCA on mitochondrial ho-
meostasis in the striatum of animals subjected to long-term
MPTP treatment, the levels of parkin were determined by
Western blot. Results presented in Fig. 6 show that total parkin
levels significantly decrease in the striatum of MPTP-treated
animals (p < 0.05, Fig. 6a and b). Phosphorylated parkin
(Ser65) levels tend to decrease in MPTP-treated animals,
?>and are partially reverted in TUDCA-treated animals, despite
the fact that this increase is only significant in animals treated
with TUDCA before MPTP (p < 0.05 vs MPTP, Fig. 6a and c).
As expected, the levels of PARIS, a parkin target that inhibits
mitochondrial biogenesis [26], were increased in the striatum
from MPTP-injected mice (p < 0.05, Fig. 6a and d).
Importantly, TUDCA treatment reverted the increase of PARIS
expression levels triggered by MPTP injection (p < 0.05
vs MPTP, Fig. 6a and d). We next evaluated voltage-
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Fig. 6 TUDCA modulates the expression of mitochondrial homeostasis
proteins in mouse striatum. Representative immunoblots (a) and
respective quantification of parkin (b), p-parkin (c), PARIS (d), VDAC
(e), and DJ-1 (f) are shown for striatum extracts. Mice were treated with
vehicle, MPTP, TUDCA prior to MPTP or TUDCA after MPTP, and
were sacrificed 52 days p.i. β-Actin was used as loading control.
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ANOVAwith Bonferroni’s post hoc test
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dependent anion channel (VDAC) expression as a readout of the
mitochondrial pool. Results presented in Fig. 6a and e show that
in animals treated with TUDCA before MPTP administration,
the expression levels of VDAC were significantly higher as
compared with MPTP-injected animals (p < 0.05 vs MPTP,
Fig. 6a and e). In accordance, DJ-1 levels were significantly
increased in the striatum of animals treated with TUDCA after
MPTP administration, comparing to vehicle-treated mice
(p < 0.05, Fig. 6a and f). Furthermore, the levels of this protein
were also significantly increased in the striatum of animals treat-
ed with TUDCA before or after MPTP administration, compar-
ing to MPTP-treated mice (p < 0.05 and p < 0.01).
Altogether these results indicate that TUDCA treatment
affects mitochondrial homeostasis proteins in the striatum in
long-term MPTP-intoxication, suggesting that this is one of
the mechanisms underlying the neuroprotective role of this
bile acid in PD.
Role of TUDCA on MPTP-Induced Glial Activation
and Neuroinflammation
Glial activation in striatum and SNpc was evaluated by deter-
mination of GFAP or Iba-1 expression levels, markers for
astro- and microgliosis, respectively. In the striatum and mid-
brain from MPTP-treated mice, GFAP expression levels were
significantly increased (p < 0.05 (striatum) and p < 0.001
(midbrain), Fig. 7a). Importantly, astrocyte activation was
completely prevented in animals treated with TUDCA prior
to MPTP in the striatum (p < 0.01 vs MPTP), and in animals
treated with TUDCA prior to or after MPTP in the midbrain
(p < 0.05 vs MPTP). Accordingly, results from Fig. 7b show
that Iba-1 expression levels were significantly higher in stria-
tum and midbrain fromMPTP-treated mice (p < 0.001). Once
again, pre- and post-treatment with TUDCA completely
prevented MPTP-induced Iba-1 expression (p < 0.001 vs
MPTP).
To better assess the role of MPTP and TUDCA on neuro-
inflammation, the levels of the cytokine interleukin-1β (IL-
1β) and of the pro-inflammatory enzyme cyclooxygenase-2
(COX-2) were also determined in the striatum. Previous stud-
ies have described that the expression of inflammatory medi-
ators occurs short after MPTP administration [53–55].
Therefore, here we used striatal samples from animals treated
with MPTP for 3 h in the presence or absence of TUDCA
(short-term evaluation scheme). As expected, our results show
that MPTP treatment leads to a rapid and significant increase
of both IL-1β and COX-2 protein levels. Importantly, admin-
istration of TUDCA before and after MPTP prevented the up-
regulation of these pro-inflammatory agents (p < 0.01 vs
MPTP, Fig. 8a–c). On the other hand, the expression levels
of Annexin-A1 (ANXA1), an anti-inflammatory protein [56],
were significantly decreased in MPTP-treated animals
(p < 0.01, Fig. 8d). Importantly, mice that received TUDCA
prior to or after MPTP injection exhibited striatal ANXA1
expression that did not differ from vehicle-treated mice (Fig.
8d), indicating that TUDCA prevents the MPTP-induced de-
crease of ANXA1 levels.
Together these results show thatMPTP induces a rapid pro-
inflammatory state, which is maintained throughout time, in
both striatum and midbrain, and is efficiently prevented when
animals are treated with TUDCA either before or after the
neurotoxin.
Discussion
Using the in vivo MPTP mouse model of PD, we evaluated
whether treatment with the bile acid TUDCA was able to
alleviate motor symptoms, and investigated the possible
mechanisms underlying its neuroprotective effects.
The first objective of this study was to extensively charac-
terize motor behavior impairment in MPTP-injected mice.
Here we show that even an acute MPTP administration in-
duced significant long-term alterations in general motor per-
formance paradigms, namely increased latency in the motor
swimming test, as well as altered gait and foot dragging. It is
controversial whether MPTP administration has an impact in
motor performance in the classical rotarod test [37, 38]. In our
experiments, we could not detect any effect of MPTP in the
rotarod test performance nor in the balance beam test, suggest-
ing that the balance of these animals was preserved after
MPTP administration. Regarding tests aiming to assess spe-
cific PD symptoms, as expected, spontaneous activity was
decreased by MPTP injection, as well as the capacity to initi-
ate movement, assessed by the adhesive removal test, the pole
test and the time to initiate movement in an open arena.
Interestingly, in the pole test, no differences were found in
the time that the animals took to reach the cage. However, in
this test, we observed an increased time to initiate movement,
which is in accordance with the core symptomatology of PD.
Importantly, MPTP-treated animals also exhibited tremors.
This supports the face validity of this animal model of PD,
reinforcing its relevance for pre-clinical studies.
Strikingly, TUDCA administration, prior to or after MPTP,
significantly prevented the MPTP-mediated increase in swim-
ming latency, improve gait quality and decrease foot dragging.
TUDCA treatment also prevented the decrease of spontaneous
activity and ability to initiate movement, as well as the tremors
induced by MPTP.
Regarding gait quality and spontaneous activity, the dele-
terious effects of MPTP were progressively reduced through-
out time. This functional recovery effect is reported in the
literature and may be caused by increased dopamine turnover
in the remaining dopaminergic neurons [57] or by increased
dopaminergic receptors in the post-synaptic cells [58], but
additional studies are needed to better understand the
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mechanisms employed here. Nonetheless, long-lasting MPTP
effects were observed in the motor swimming test, in the foot
dragging phenotype, in the adhesive removal test, in the pole
test, in the time to initiate movement, in tremors and in
hindlimb clasping at day 45 after MPTP administration.
Interestingly, the paw-clasping phenotype is observed in sev-
eral mouse models with damaged basal ganglia, including
those pharmacologically induced by MPTP [52, 59], and here
we show that it was ameliorated by TUDCA treatment.
Overall, results show thatMPTP-injected mice present mo-
tor symptoms that resemble human parkinsonism. Moreover,
as in humans, motor symptoms were aggravated throughout
time in parkinsonian mice, proving that the experimental
paradigm is adequate. Strikingly, in TUDCA-treated animals
PD motor symptoms were absent or mild, and no aggravation
was observed in any evaluated parameter. In a medical per-
spective, in the context of a chronic progressive neurodegen-
erative disease like PD, these results are significant. TUDCA
may prevent neurodegeneration of still healthy neurons and
glial activation, keeping a larger pool of dopaminergic neu-
rons, which may account for the delay of disease and symp-
toms progression.
Behavioral deficits were accompanied by a loss of TH-
positive fibers in the striatum, analyzed 52 days after acute
MPTP administration. Importantly, TUDCA treatment
prevented the loss of TH-positive fibers in the striatum
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Fig. 7 TUDCAmodulates glial activation in the striatum andmidbrain of
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confirming our previous observations [33, 35]. In a recent
study, we have also shown that TUDCA protects neurons
against MPP+-induced cell death [35], and this bile acid was
also neuroprotective in other experimental models of neuro-
degenerative diseases [29–32], further strengthening our cur-
rent results. The neuroprotection of dopaminergic cells by
TUDCA may explain the maintenance of ATP levels when
animals were treated with the bile acid.
Loss-of-function mutations of parkin are the major cause
of recessively inherited early-onset PD and wild-type
parkin may also be inactivated by post-translational modi-
fications in sporadic PD [24, 60], which leads to impaired
mitochondrial turnover. Herein we observed that MPTP-
injected mice showed significantly decreased expression
of parkin, whereas treatment with TUDCA maintained
parkin levels and most notably of phosphorylated parkin
in the striatum. PARIS, a parkin target that accumulates
upon parkin inactivation, was concomitantly increased in
the striatum of MPTP-injected mice, but not when animals
were treated with TUDCA. These results are in accordance
with our previous observations, showing that TUDCA trig-
gers parkin expression and phosphorylation in the striatum
of MPTP-injected mice [35]. We have previously demon-
strated that parkin activation is an early event occurring
in vivo after MPTP administration [35]. Moreover, we have
also shown using in vitro systems that parkin mediates
some of the neuroprotective effects of TUDCA in neuronal
cells upon MPP+ exposure [35]. Interestingly, here we
show that modulation of parkin by TUDCA in the presence
of MPTP is maintained throughout longer time periods,
confirming that this activation is an important mechanism
underlying TUDCA neuroprotective role in experimental
PD. The fact that parkin is involved in mitochondrial turn-
over makes it a perfect candidate to be a TUDCA mediator.
The pharmacological upregulation of parkin by TUDCA is
crucial in the context of PD and other neurodegenerative
disorders where mitochondria also play a key role, and
deserves further investigation.
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Additionally, parkin and DJ-1 form a complex to promote
degradation of misfolded proteins and their PD-pathogenic
mutations impair E3 ligase activity of the complex [61].
Interestingly, DJ-1 protein expression was increased in the
striatum of animals treated with TUDCA. This is also in ac-
cordance with our previous observations, in the striatum and
midbrain from mice treated with MPTP for 3–6 h, showing
that DJ-1 expression was upregulated when animals received
TUDCA before MPTP [34]. These results suggest that DJ-1 is
also an important target protein mediating TUDCA neuropro-
tective effects in vivo.
Taking in consideration our previous and present work,
data strongly indicate that TUDCA promotes neuroprotection
through the maintenance of a healthy mitochondrial pool in
MPTP-intoxicated mice.
Besides mitochondrial dysfunction, neuroinflammation
and glial activation are also hallmarks of PD [7, 9, 11–13].
Here we have measured the expression levels of IL-1β and
COX-2 as surrogate markers of inflammation in the striatum.
Accordingly, MPTP-treated mice exhibited an early over-
expression of these inflammatory mediators, and subsequent
astro- and microglyosis both in the striatum and the midbrain.
The early protein changes in inflammatory mediators have
already been described after MPTP insult [53–55] and may
be the consequence for long-term sustained glial activation. In
fact, sustained glial activation in the surrounding environment
of dopaminergic injured cells is in accordance with previous
reports [20, 62]. Accordingly, IL-1β levels have already been
shown to be increased in PD brains [7] and the deletion of the
pro-inflammatory enzyme COX-2 in mice protects from
MPTP-induced dopaminergic cell loss [63]. Besides its ability
to impair oxidative stress, TUDCA has recently been
shown to have an anti-inflammatory role in glial cultures
and in an experimental mouse model of neuroinflammation
[64, 65]. However, to the best of our knowledge, there is no
available data concerning the effect of TUDCA on neuro-
inflammation and glial activation in models of PD.
Interestingly, TUDCA prevented the induction of IL-1β
and COX-2 expression and glial activation when adminis-
tered both before and after MPTP. Furthermore, we have
shown that ANXA1, an anti-inflammatory protein, which
is able to decrease ROS and neuroinflammation by reduc-
ing the expression levels of pro-inflammatory cytokines
[66], is decreased in the striatum of MPTP-injected mice
but not when animals were treated with TUDCA.
Altogether, our results suggest that one of the mechanisms
underlying TUDCA neuroprotective effect towards MPTP
toxicity may be the modulation of glial activation and neu-
roinflammation. The changes in these inflammatory mole-
cules precede or are coincident with the manifestation of
MPTP-induced damage in the striatum. Therefore, they
may contribute to nerve damage and cell loss and/or be a
response to those processes. The fact that TUDCA
efficiently prevented the inflammatory reaction further
contributes to the validation of its neuroprotective role.
Although we found that TUDCA was not protective to-
wards MPTP acute toxicity, the results presented here are
promising and indicate that TUDCA improves motor perfor-
mance in MPTP-intoxicated mice, although longer/higher
TUDCA dosage, as well as different time-points of adminis-
tration following MPTP injection, should be optimized to ex-
tend the neuroprotection. The demonstration of the prevention
and/or the alleviation of symptoms together with the demon-
stration of the pathways triggered by TUDCA should contrib-
ute to a subsequent clinical trial in humans and future valida-
tion of the therapeutic application of this bile acid in PD.
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